We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Daniel J. Lahar
Daniel J. Lahar
Products
PRODUCTS
Respironics California, LLC
Daniel J. Lahar
Price:
$117.00
View
Encore Medical, LP
Daniel J. Lahar
Price:
$117.00
View
Linatech, LLC
Daniel J. Lahar
Price:
$117.00
View
Ningbo Besmed Medical Equipment
Daniel J. Lahar
Price:
$117.00
View
Clinicon Corp.
Daniel J. Lahar
Price:
$117.00
View
Dental Engineering Laboratories, LLC
Daniel J. Lahar
Price:
$117.00
View
Emerge Diagnostics, Inc.
Daniel J. Lahar
and
Juanj N. Wu
Price:
$117.00
View
Sotera Wireless, Inc.
Daniel J. Lahar
Price:
$117.00
View
Scantibodies Laboratory, Inc.
Daniel J. Lahar
Price:
$117.00
View
International Medical Development, Inc.
Daniel J. Lahar
Price:
$117.00
View
View All Products by Daniel J. Lahar
Upcoming Events
10
Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
08
Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15
Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20
Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21
Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22
Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
Pulse Biosciences’ CellFX Gets 510(k) Clearance for Expanded Energy Settings
Merck to Face MDL Regarding Gardasil HPV Vaccine Side Effects
Hyris T-Cell Test Gains CE-IVD Mark
FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
